Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Dare Bioscience's share price for the quarter that ended in Sep. 2024 was $3.24. Dare Bioscience's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 8.55 Mil. Therefore, Dare Bioscience's market cap for the quarter that ended in Sep. 2024 was $27.69 Mil.
Dare Bioscience's quarterly market cap
declined
from Mar. 2024 ($49.31 Mil) to Jun. 2024 ($34.47 Mil) and
declined
from Jun. 2024 ($34.47 Mil) to Sep. 2024 ($27.69 Mil).
Dare Bioscience's annual market cap
declined
from Dec. 2021 ($167.89 Mil) to Dec. 2022 ($70.41 Mil) and
declined
from Dec. 2022 ($70.41 Mil) to Dec. 2023 ($30.89 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Dare Bioscience's Enterprise Value for Today is $17.93 Mil.
Dare Bioscience Market Cap Historical Data
The historical data trend for Dare Bioscience's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dare Bioscience's Market Cap
For the Biotechnology subindustry, Dare Bioscience's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dare Bioscience's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dare Bioscience's Market Cap distribution charts can be found below:
* The bar in red indicates where Dare Bioscience's Market Cap falls into.
Dare Bioscience Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Dare Bioscience's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dare Bioscience (NAS:DARE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Dare Bioscience Market Cap Related Terms
Thank you for viewing the detailed overview of Dare Bioscience's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DARE has been successfully added to your 